WP: Secret contracts reveal undisclosed terms in Trump’s drug-pricing deals
Public Citizen said the redacted contracts leave key pricing terms hidden, including carveouts for GLP-1 drugs and clauses that could affect Medicaid savings.
- On Saturday, HHS released two of 27 confidential drug-pricing agreements following a Public Citizen lawsuit, though documents including the first White House deal with Pfizer and Eli Lilly's agreement remain heavily redacted.
- Public Citizen filed a FOIA lawsuit in January to compel the Department to produce the records. Legal action forced release of these previously secret MFN pricing templates.
- Pfizer's agreement supersedes the GENEROUS Medicaid model, while Eli Lilly's deal excludes blockbuster GLP-1s from discounts. Analysts warn a similar Novo carveout could reduce potential savings by $1.7 billion.
- Peter Maybarduk, Access to Medicines Director for Public Citizen, called the deals a 'mirage' creating minimal downside for Big Pharma. The agreements expire at the end of the president's term.
- Ongoing heavy redactions prevent independent verification of Trump administration claims regarding lowered drug prices. Public Citizen analysis indicates the public cannot rely on the administration's previous representations.
12 Articles
12 Articles
If Trump wants to lower drug prices, his obvious free-riding targets are outside the US – Democratic Accent
President Donald Trump just secured nine new pricing agreements with drug manufacturers that could help... The post If Trump wants to lower drug prices, his obvious free-riding targets are outside the US appeared first on Democratic Accent .
If Trump wants to lower drug prices, his obvious free-riding targets are outside the US - NEW YORK TIMES POST
NEWYou can now listen to Fox News articles! President Donald Trump just secured nine new pricing agreements with drug manufacturers that could help reduce what Americans pay for many prescription medicines. The deals demonstrate Trump’s commitment to lowering drug prices for patients. The president’s dedication – and his desire to negotiate with companies individually, rather [...]
Secret Drug Pricing Deals Include Tariff Protections
The Washington Post reports: The Trump administration’s confidential deals with pharmaceutical companies to lower U.S. drug prices include inducements to raise drug prices overseas and promise protection from President Donald Trump’s tariffs, according to documents shared with The Washington Post. The documents, obtained through Freedom of Information Act lawsuits, detail negotiations between the administration and … The post Secret Drug Pricing…
Coverage Details
Bias Distribution
- 37% of the sources lean Left, 36% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
